Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C

Trial Profile

Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs BMS 986094 (Primary) ; Daclatasvir; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 Nov 2013 Planned End Date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 23 Aug 2012 Status changed from suspended to withdrawn prior to recruitment prior to recruitment.
    • 06 Aug 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top